BofA Cautious on Hims and Hers (HIMS): 'HIMS to offer Lilly’s Zepbound, expect minimal revenue contribution'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall St set for higher open tech gains offset bond-market jitters
- Oil prices rise as China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- Alphabet shares up in premarket trade after Gemini 4 Argon launch
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
Leerink Cautious on Hims and Hers (HIMS): 'we still have yet to see how the LT growth profile of HIMS' weight loss business can look like'
April 1, 2025 4:08 PM EDTLeerink Partners analyst Michael Cherny reiterated a Market Perform rating and $40.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "The addition of Eli Lilly's (LLY, OP, Risinger) Zepbound (which was unexpected) and generic liraglutide (which was expected) should help... More
Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform
April 1, 2025 1:39 PM EDTBy Sneha S K and Puyaan Singh
(Reuters) - (This April 1 story has been corrected to say that the company also offers the branded version of Wegovy, not just cheaper versions of the treatment, in paragraph 3. It was previously corrected to change the brokerage's name to Leerink Partners, not Jefferies, in paragraph 4)
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on selling copies of Novo Nordisk's obesity drug.
... MoreHims & Hers Health (HIMS) expanding access to personalized weight loss care
April 1, 2025 1:30 PM EDT(Updated - April 1, 2025 1:31 PM EDT)
Hims & Hers Health, Inc. (NYSE: HIMS) press release:
In my experience of treating thousands of people, lasting results come from focusing on the individual, not just the condition.
This simple belief has shaped the way we've built the Hims & Hers platform and is especially important in how we designed our weight loss offering, because we know that the condition and the treatment is never one-size-fits-all. Were committed to bringing our customers more treatment options that best suit their needs, and weve now expanded... More
Hims & Hers Health, Inc. (HIMS) said to sell Lilly's Zepbound
April 1, 2025 1:04 PM EDTHims & Hers Health, Inc. (NYSE: HIMS) said to sell Lilly's Zepbound via its telehealth platform.
shares up 8%... MoreHims & Hers Health, Inc. (HIMS) call put ratio 1.7 calls to 1 put
March 28, 2025 6:23 AM EDTHims & Hers Health, Inc. (NYSE: HIMS) 30-day option implied volatility is at 92; compared to its 52-week range of 47 to 146. Call put ratio 1.7 calls to 1 put.
... More